BioSpace News Archive

Transparency Market Research has published a new report titled ‘Transfusion Technology Market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2018–2026’.

Hutchison China MediTech Limited announces that Mr Christian Hogg, Chief Executive Officer of Chi-Med, will participate in a virtual fireside chat at the Bank of America 2020 Health Care Conference on Thursday, May 14, 2020 9:40 a.m. Eastern Daylight Time.

Recently presented promising XMT-1536 Phase 1 dose escalation data and established maximum tolerated dose, subsequently raising $65M of gross proceeds from the Company’s ATM facility Company to present interim data from the ongoing XMT-1536 Phase 1 dose expansion on a conference call on May 27, 2020 and at the upcoming American Society of Clinical Oncology (ASCO) 2020 virtual scientific program CAMBRIDGE, Mass., May 08, 2020 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a

Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) a clinical stage company developing new drug candidates for treating organ damage caused by inflammation, today announced it has received a No Objection Letter from Health Canada to conduct a Phase II human trial for its lead drug LSALT peptide (Metablok) to prevent organ inflammation experienced by patients with COVID-19. The Phase II trial will be a multicenter, r

Net sales of $104.8 million, a decrease of 3.9% compared to prior year and 3.4% on a constant currency basis Cost management initiatives put in place to reduce cash burn Borrowed $100.0 million against the secured revolving credit facility to navigate uncertain macro-environment Closed the acquisition of the FITBONE intramedullary lengthening system assets

Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that in the interest of the health and safety of its shareholders, directors, officers, employees and meeting attendees in light of the current COVID-19 pandemic and the declared state of emergency in New Jersey, the format of its 2020 Annual Meeting of Shareholders has been changed to a virtual meeting. Merck’s 2020 Annual Meeting will b

Apellis Pharmaceuticals , Inc. (Nasdaq: APLS) a global biopharmaceutical company pioneering targeted C3 therapies, today announced that the company will present at the BofA Securities 2020 Health Care Conference on Thursday, May 14, 2020 at 8:20 a.m. ET. The conference will be held in a virtual meeting format. Cedric Francois, M.D., Ph.D., co-founder and chief executive officer of Apellis, will participate in a fireside chat. The event will

Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, today reported financial results for the first quarter ended March 31, 2020. “Our team remains focused on progressing our programs as we navigate the evolving business and regulatory environment,” said George Lasezkay, Pharm.D., J.D., Presiden

Clinical successes highlight Axsome’s accelerated evolution into a leading CNS company Positive pivotal Phase 2/3 results for AXS-05 in Alzheimer’s disease agitation further deepen innovative pipeline Positive efficacy results in 5 significant CNS indications with 4 candidates advance broad late-stage pipeline Two NDA submissions, for AXS-05 in MDD and AXS-07 in migraine, on track for 4Q 2020 Pre-commercialization activities underway for potentially first-in-class or best-in-class C

NGM Biopharmaceuticals, Inc. announced that, due to public health and safety concerns related to the coronavirus pandemic, recommendations and orders from federal, state and local authorities, and to support the health and well-being of its stockholders, employees, and others, it will host its 2020 Annual Meeting of Stockholders as a virtual-only meeting that will be held via live audio webcast.